Stealth Syndromes Human Study — Approved by the University of California, San Francisco Medical School’s Committee on Human Research in 2015, this is the controlled first human study of environmental chemicals. This effort is the #1 priority for CRECH.
The Stealth Syndromes Project — This multi-year endeavor began as an effort to clarify environmental risks for a non-scientific audience.
After writing scores of articles based upon the study of hundreds of published, peer-reviewed studies, project founders Perdue and Yeamans-Irwin realized that no adequate science existed that could justify valid decisions based on causation.
They realized that to move beyond non-causal links and associations based on animal studies and epidemiology, they needed to create the missing science. With the the collaboration of UCSF Professor and Victor Reus, that study was developed and approved by the UCSF/CHR.
PharmBlockers — Using existing pharmaceutical evaluation results as a more accurate paradigm for assessing environmental chemical risks — This is a fledgling effort that has resulted from Stealth Syndrome Project research which discovered that some environmental chemicals work in ways that counteract approved pharmaceuticals.
More specifically, those environmental chemicals work in direct opposition to the exact same cellular mechanisms targeted by drugs. As one example, published studies indicate that Bisphenol A promotes resistance to cancer chemotherapy, thus making treatment less effective. This is especially significant given that most plastic intravenous tubing leaches BPA and associated environmental chemicals.
This example of a “PharmBlocker” suggests that those environmental chemicals need to be evaluated with the same degree of scrutiny as the pharmaceutical whose effects they harm.